Untying the knot: protein quality control in inherited cardiomyopathies

Larissa M. Dorsch 1 · Maike Schuldt 1 · Dora Knežević 1 · Marit Wiersma 1 · Diederik W. D. Kuster 1 · Jolanda van der Velden 1 · Bianca J. J. M. Brundel 1

Received: 30 July 2018 / Accepted: 6 August 2018 / Published online: 14 August 2018
© The Author(s) 2018

Abstract

Mutations in genes encoding sarcomeric proteins are the most important causes of inherited cardiomyopathies, which are a major cause of mortality and morbidity worldwide. Although genetic screening procedures for early disease detection have been improved significantly, treatment to prevent or delay mutation-induced cardiac disease onset is lacking. Recent findings indicate that loss of protein quality control (PQC) is a central factor in the disease pathology leading to derailment of cellular protein homeostasis. Loss of PQC includes impairment of heat shock proteins, the ubiquitin-proteasome system, and autophagy. This may result in accumulation of misfolded and aggregation-prone mutant proteins, loss of sarcomeric and cytoskeletal proteins, and, ultimately, loss of cardiac function. PQC derailment can be a direct effect of the mutation-induced activation, a compensatory mechanism due to mutation-induced cellular dysfunction or a consequence of the simultaneous occurrence of the mutation and a secondary hit. In this review, we discuss recent mechanistic findings on the role of proteostasis derailment in inherited cardiomyopathies, with special focus on sarcomeric gene mutations and possible therapeutic applications.

Keywords

Cardiomyopathy · Protein quality control · Sarcomeric mutation · Heat shock proteins · Ubiquitin-proteasome system · Autophagy

Classification of cardiomyopathies

Cardiomyopathies (CM) constitute one of the most common causes of sudden cardiac death in young adults and represent major causes for cardiac transplantation [88]. Disease onset generally ranges between 20 and 50 years of age. CMs are defined by abnormal myocardial structure and function in the absence of any other diseases sufficient to cause these abnormalities [24]. These can be sub-classified based on their functional phenotype and their specific morphological changes. The most common types are hypertrophic CM (HCM), characterized by increased left ventricular (LV) wall thickness often occurring asymmetrically, and dilated CM (DCM), in which the presence of LV dilatation is accompanied by contractile dysfunction [24]. Besides HCM and DCM, there are less frequent forms, such as restrictive CM (RCM) and desmin-related cardiomyopathy [24]. All these cardiomyopathies can be familial and are typically inherited in an autosomal dominant manner. Mutations in genes encoding sarcomeric proteins are the most common cause of these types of CMs [3]. However, the genotype-phenotype relationship is far from clear. The variations in age of CM onset and disease phenotype suggest that additional factors play a role in CM pathogenesis.

Accumulating evidence indicates the presence of derailed proteostasis in CMs as well as its contribution to CM onset and progression. This derailment could either be caused directly by the mutation or indirectly due to a compensatory mechanism. In the former case, the mutant protein might be unstable or improperly folded leading to direct activation of the protein quality control (PQC). In the latter case, the mutation does not interfere with protein folding or stability but causes functional impairment, which in turn leads to cellular stress and indirect activation of the PQC. Furthermore, the “secondary-hit” model may apply in CMs, in which a primary sarcomere mutation enhances vulnerability to secondary...
stressors, which increases cellular burden resulting in PQC derailment. This review summarizes the current knowledge about perturbations in the different components of the PQC in CMs that are caused by mutations in sarcomeric proteins.

**Proteostasis network ensures cardiac health**

The heart has a very limited regenerative capacity and therefore requires surveillance by a system that maintains protein homeostasis to ensure cardiac health [106]. The PQC system sustains proteostasis by refolding misfolded proteins or removing them if refolding is impossible. It is composed of heat shock proteins (HSPs), the ubiquitin-proteasome system (UPS), and autophagy. PQC is only then functional when all three components are operative and interact with each other. This means that derailment of one of the parts might impair the function of the others in a direct or indirect manner. In a physiological state, protein folding and refolding is ensured by HSPs and their regulators. Terminally misfolded and aggregation-prone proteins are cleared by the two degradation systems, i.e., the UPS and autophagy that work in collaboration with the HSPs (Fig. 1).

First, the different parts of the PQC in normal physiology are described, before addressing their role in CMs.

**Heat shock proteins**

HSPs, originally identified as heat responsive proteins, are constitutively expressed in the cell to serve as molecular chaperones to ensure correct folding and assembly of proteins. HSPs are classified in two categories: the small HSPs with a low molecular weight (15–30 kDa) and the chaperones with a high molecular weight (> 30 kDa).

One functional group of HSPs are chaperonin complexes, which are ATP-dependent chaperones with a barrel-like structure that provide correct folding of nascent proteins after translation. Besides their folding function during protein translation, HSPs are also induced in response to cellular and environmental stressors to maintain a healthy cellular proteostasis by clearance of misfolded proteins [66, 111].

As reviewed by Garrido et al., small HSPs show an ATP-independent holdase activity. This means that they bind to misfolded proteins, keep them in a state competent for either refolding or degradation, and thereby prevent or attenuate their aggregation. Due to the association of small HSPs with the HSPs that have an ATP-dependent folding activity, the misfolded proteins can be refolded into their native and functional conformation [28]. The binding affinity of HSPs to the misfolded protein is dependent on the chaperone cofactors bound to the HSPs. Furthermore, this binding of chaperone cofactors determines...
the processing of the misfolded protein for either refolding or degradation. Chaperone cofactors involved in degradation pathways can switch off the refolding activity of HSPs by inhibiting their ATPase activity and assist the HSPs and the UPS or autophagy in the breakdown of misfolded proteins (Fig. 2) [13, 25]. The degradation of the thick filament protein myosin-binding protein C (MyBP-C), for instance, is mediated via the chaperone cofactor HSC70 playing a major role in regulating MyBP-C protein turnover [32]. These degradation pathways are addressed in the following sections.

To maintain the structure and function of the highly dynamic cardiac sarcomeres, HSPs play an important role. The molecular chaperones GimC (Prefoldin), chaperonin TCP-1 Ring Complex (TRiC), αB-crystallin, and HSP27 ensure correct folding and assembly of proteins, maturation of actin and prevent aggregate formation [10, 14, 34, 36]. HSP27 is mostly found as high-molecular weight oligomers in the cytosol of unstressed cells [23]. Upon stress, HSP27 deoligomerizes and translocates to F-actin and thereby stabilizes the F-actin network [16]. To assemble the myosin thick filament, the chaperones UNC-45, HSP90, and HSP70 are required, whereas the actin filament is self-assembled [7, 8, 94]. Several members of the small HSPs family are expressed in the heart and associate with cytoskeletal proteins [33, 103]. These HSPBs stabilize cytoskeletal structures and improve coping with stress situations [33, 48, 49].

Ubiquitin-proteasome system

In case of terminally misfolded proteins, that failed to be refolded, HSPs and their chaperone cofactors recruit enzymes to mediate polyubiquitination of the target substrate and thereby mark them for the appropriate degradation pathway. Short-lived proteins are typically degraded by the UPS, whereas autophagy is mainly used for degrading long-lived proteins and entire organelles [17, 39].

The polyubiquitination of the target substrate requires the sequential action of three enzymes. The ubiquitin-activating enzyme (E1) activates ubiquitin, which is then transferred to a ubiquitin-conjugating enzyme (E2). In the last step, a ubiquitin ligase (E3) links ubiquitin from the E2 enzyme to a lysine residue of the target protein. There are only two E1 enzymes, several E2 enzymes, and many E3 ligases, each of which recognizes one or several specific protein motifs. Therefore, the substrate specificity is achieved by the selectivity of the different E3 ligases [26, 80]. Dependent on the combination of E2 enzyme and E3 ligase, polyubiquitin chains are linked to the preceding ubiquitin molecule either via lysine 48 (K48) or via lysine 63 (K63), which marks the protein for degradation. Therefore, the polyubiquitination process determines the degradation pathways: Proteins carrying K48-linked polyubiquitin chains are predominantly targeted to proteasomal degradation, and proteins carrying K63-linked polyubiquitin chains enter the autophagic pathways as discussed in the following paragraph [1].

K48-linked polyubiquitinated proteins are transferred to the proteasome, which is almost exclusively the 26S proteasome in eukaryotic cells. This protein complex consists of one 20S core- and two 19S regulatory subunits forming a barrel-like structure. The regulatory subunits have ubiquitin-binding sites to recognize polyubiquitinated proteins and unfold them using their ATPase activity. The unfolded proteins are transferred to the catalytic core and proteolytically cleaved [104].

Sarcomeric proteins have an average turnover rate of 5–10 days [12, 112]. Therefore, they rely on a proper functioning UPS to regulate their clearance. Once dissociated from the myofibrils, ubiquitin-conjugating enzymes mark the proteins for proteasomal degradation by adding K48-linked

---

**Fig. 2** Chaperone cofactor binding determines the heat shock protein (HSP) function. Small HSPs (white/gray rectangle) and HSPs with ATPase activity (blue moon shape with black rectangle) bind to the misfolded protein to stabilize it. Dependent on the chaperone cofactors (green circles or turquoise squares), the misfolded protein gets either refolded or ubiquitinated for subsequent degradation. If refolding is impossible, the chaperone cofactors can be exchanged to promote degradation. In case of ubiquitination, the chaperone cofactors can switch off the HSP refolding activity by blocking the ATPase activity and, together with HSPs, assist in clearance of the misfolded protein via the degradation pathways.
polyubiquitin chains [91, 112]. In cardiomyocytes, this step is mediated by the MuRF family of E3 ligases [59, 93].

**Autophagy**

Autophagy cleans up aggregates or proteins via lysosomal breakdown that cannot be refolded by chaperones or processed by the UPS [46]. During macroautophagy, herein referred to as autophagy, membrane-enclosed vesicles are formed containing the targeted cellular components. First, an isolation membrane is formed engulfing the cytoplasmic material. The membrane expands until the edges fuse to form the autophagosome [118]. Fusion of the autophagosome with a lysosome leads to an autolysosome, which breaks down the cargo [5]. During selective autophagy, proteins carrying a K63-linked polyubiquitin chain are degraded. In the case the proteasome is overwhelmed with proteins carrying a K48-linked ubiquitin chain, such as aggregated proteins, they can also be cleared via autophagy. Their polyubiquitin chain docks to the adaptor protein p62/SQSTM1, which enables the translocation into the autophagosome [45]. Acidic lysosomal hydrolases degrade the captured material together with the inner membrane, and the resulting macromolecules are recycled into ATP, amino acids and fatty acids.

Autophagy is found to be upregulated in response to starvation, growth factor withdrawal, or high bioenergetic demands [50, 56, 65, 86]. The ability to sequester and breakdown organelles, such as mitochondria, peroxisomes, endoplasmic reticulum, and intact intracellular microorganisms, makes autophagy a unique and essential process in the cell. Especially in post-mitotic cells like cardiomyocytes, basal activation of autophagy is important to maintain a balanced proteostasis by degradation of long-lived proteins, lipid droplets, and dysfunctional organelles [17].

Cardiomyocytes have a low basal autophagic activity under normal conditions. Upon stress, the formation of protein aggregates is facilitated and triggers activation of autophagy [96]. Furthermore, cardiac autophagy is initiated in response to energy stress during periods of nutrient deprivation or high metabolic demand [35].

**Proteostasis derailment in inherited cardiomyopathies**

The PQC is of great importance in many cardiac diseases caused by “wear and tear,” including cardiac amyloidosis, myocardial infarction, and atrial fibrillation [37, 60, 73, 115]. The activation of PQC in a variety of cardiac stress conditions can be considered as a positive compensatory response to maintain proteostasis. This might be especially true in the case of inherited CMs, where mutant protein expression is the disease-causing mechanism. Recent studies provide evidence for a causative role of the PQC in CM. On one hand, mutations in components of the PQC itself can cause CM. This has been described for the R120G mutation in CRYAB encoding for the chaperone αB-crystallin, causing desmin-related CM, and the P209L mutation in the chaperone cofactor BAG3, leading to juvenile DCM [87, 105]. Mutations in PQC components as causes of inherited CM are rare, but PQC impairment can also occur as a result of CM-causing sarcomeric mutations. In this case, mutant sarcomeric proteins may impair the function of the PQC through overload of its components including HSPs, UPS, and autophagy. This could lead to increased levels of mutant protein, exacerbating CM disease progression.

So far, the role of PQC has been investigated only in a limited number of studies on CM caused by sarcomeric gene mutations. In vitro information is available for HCM- and DCM-causing mutations in ACTC1. Furthermore, it has been studied in vivo with HCM-causing mutations in MYBPC3, MYH7, and MYOZ2; DCM-causing NEBL mutations; and RCM-causing TNNI3 mutations (Table 1). In the following sections, the interaction between CMs and derailments of the different parts of the PQC are described in detail.

**Diverse abnormalities in heat shock protein function**

HSP impairment or activation contribute to disease pathology in CMs. Desmin-related CM displays HSP impairment and is either caused by mutant desmin itself or mutant chaperone αB-crystallin. In a normal state, αB-crystallin binds to desmin and thereby prevents its aggregation [10]. Mutant desmin, however, impairs the interaction with αB-crystallin leading to desmin accumulation and cardiomyocyte dysfunction [54]. This suggests aberrant protein aggregation can cause CM. Correspondingly, the R120G mutation in CRYAB results in desmin-related CM as well and also presents with aggregates containing desmin and mutant αB-crystallin [105]. Sanbe et al. showed that upregulation of HSPB8 due to geranylgeranylacetone treatment reduces the amount of mutant αB-crystallin-containing aggregates [83]. This implies that other HSPs can compensate for the loss of function to remove aggregates. Furthermore, in vitro experiments have shown that HCM- or DCM-causing mutations in ACTC1, encoding cardiac actin, can interfere with its folding by the TRiC chaperonin complex resulting in inefficient incorporation of actin into the myofilament and its subsequent aggregation [102]. Mutations in one specific subdomain of actin affect protein stability or polymerization, making actin more prone for degradation. Whereas mutations in other subdomains of actin cause alterations in protein-protein interactions [67]. A gene co-expression analysis of human controls and HCM samples identified the TRiC chaperonin complex as the most differential pathway, thereby further highlighting its importance in HCM [19].
By contrast, various studies on the role of PQC in CMs report on increased levels of HSPs due to PQC activation. However, it still remains unresolved whether the increased levels of HSPs are a direct effect of the mutant protein or a compensatory secondary effect due to increased cellular stress. Therefore, the direct interaction of mutant protein and HSPs needs to be studied. In mice with a truncating MYBPC3 mutation and an HCM phenotype, increased levels of αB-crystallin have been found [116]. In other CM mouse models, independent of a sarcomeric mutation, increased levels of HSP70 have been observed [62]. A study in patients with chronic heart failure due to DCM revealed a correlation of serum HSP60 levels with disease severity [69]. Since increased levels of HSP27 and HSP70 are associated with a protective effect in models for atrial fibrillation, by maintaining cardiomyocyte function, one can speculate that increased expression of these HSPs might be part of a compensatory protective mechanism in CM [15, 62].

In general, research findings indicate that HSP impairment is detrimental for cardiomyocyte function due to a higher risk of impaired protein folding and aggregate formation. By contrast, HSP activation in CM is considered as a beneficial effect and is most likely a compensatory mechanism of the cell.

### Derailment of the ubiquitin-proteasome system

Table 1

| Gene   | Phenotype | Morphological abnormalities                                      | Chaperones | UPS | Autophagy |
|--------|-----------|------------------------------------------------------------------|------------|-----|-----------|
| ACTC1  | HCM       | not reported                                                     | + (in vitro) [102] | not reported | not reported |
|        | DCM       | not reported                                                     | + (in vitro) [102] | not reported | not reported |
|        | RCM       | not reported                                                     | not reported | not reported | not reported |
| ACTN2  | HCM       | cytoplasmic vacuolization, perinuclear halo, dysmorphic nuclei (human) [31] | not reported | not reported | not reported |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
| MYBPC3 | HCM       | large irregular vacuoles (infant) [109]                          | αB-crystallin ↑ (mice) [116] | ↓ (mice) [85] | ↑ (human) [92] |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
| MYH6   | HCM       | not reported                                                     | not reported | not reported | not reported |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
| MYH7   | HCM       | not reported                                                     | not reported | not reported | ↑ (human) [92] |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
| MYL2   | HCM       | not reported                                                     | not reported | not reported | not reported |
| MYL3   | HCM       | not reported                                                     | not reported | not reported | not reported |
|       | RCM       | ultrastructural defects (mice) [119]                              | not reported | not reported | not reported |
| MYOZ2  | HCM       | not reported                                                     | ↑ (mice) [41] | not reported | not reported |
| NEBL   | HCM       | myocyte vacuolization (human) [75]                               | not reported | not reported | not reported |
|        | DCM       | enlarged and deformed mitochondria, lipid accumulation (mice) [78] | not reported | not reported | abnormal lysosomes (mice) [78] |
| TNNC1  | HCM       | not reported                                                     | not reported | not reported | not reported |
|        | DCM       | no evidence of vacuolization (human) [43]                         | not reported | not reported | not reported |
|        | RCM       | degeneration of myocardial fibers (human) [76]                   | not reported | not reported | not reported |
| TNNI3  | HCM       | not reported                                                     | not reported | not reported | not reported |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
|        | RCM       | irregularly shaped megamitochondria (human) [117]                | not reported | ↓ proteasomal activity (mice) [20] | not reported |
| TNNT2  | HCM       | myocyte atrophy (mice) [97]                                      | not reported | ↓ (mice) [30] | not reported |
|        | DCM       | not reported                                                     | not reported | not reported | not reported |
|        | RCM       | abnormal mitochondria (human) [74]                               | not reported | not reported | not reported |
| TPM1   | HCM       | nuclear gigantism [68]                                            | not reported | not reported | not reported |
|        | DCM       | accumulation of TPM1 (mice) [79]                                 | not reported | not reported | not reported |
|        | RCM       | not reported                                                     | not reported | not reported | not reported |

Mixed genotypes are indicated with “*” and a “+” indicates a positive finding.

By contrast, various studies on the role of PQC in CMs report on increased levels of HSPs due to PQC activation. However, it still remains unresolved whether the increased levels of HSPs are a direct effect of the mutant protein or a compensatory secondary effect due to increased cellular stress. Therefore, the direct interaction of mutant protein and HSPs needs to be studied. In mice with a truncating MYBPC3 mutation and an HCM phenotype, increased levels of αB-crystallin have been found [116]. In other CM mouse models, independent of a sarcomeric mutation, increased levels of HSP70 have been observed [62]. A study in patients with chronic heart failure due to DCM revealed a correlation of serum HSP60 levels with disease severity [69]. Since increased levels of HSP27 and HSP70 are associated with a protective effect in models for atrial fibrillation, by maintaining cardiomyocyte function, one can speculate that increased expression of these HSPs might be part of a compensatory protective mechanism in CM [15, 62].

In general, research findings indicate that HSP impairment is detrimental for cardiomyocyte function due to a higher risk of impaired protein folding and aggregate formation. By contrast, HSP activation in CM is considered as a beneficial effect and is most likely a compensatory mechanism of the cell.

### Derailment of the ubiquitin-proteasome system

Derailed UPS function in CM affects the degradation of terminally misfolded proteins. MYBPC3 mutations often lead to
expression of truncated protein, which is not incorporated into the sarcomere because the most C-terminal domain needed for incorporation is missing [64]. Truncated MyBP-C has not been detected in cardiac samples of HCM patients [101]. In addition, very low levels (<4%) of truncated MyBP-C, which were not incorporated into the sarcomeres, were found in engineered heart tissue made of MYBPC3 knock-out mouse cardiomyocytes transfected with a truncating MYBPC3 mutation [110]. Therefore, it is likely that either the mutant mRNA is degraded via nonsense-mediated mRNA decay and/or the truncated MyBP-C forms a substrate for immediate degradation by the UPS or autophagy. Since MyBP-C is highly expressed in cardiomyocytes, high levels of truncated protein may lead to an increased UPS burden and competitive inhibition of the proteasome [84, 85]. In this case, the UPS is overwhelmed by the amount of truncated protein that needs to be degraded. In line with this hypothesis are analyses of myectomy samples from HCM patients with sarcomeric mutations, which show a decrease in proteolytic activity (Table 1) [77, 85]. Decreased processing through the UPS system is also indicated by the increase in overall levels of protein ubiquitination in HCM patients and animal models, which is already detectable at an early postnatal phase prior to any other symptom development [6, 30, 77, 85]. Consistent with the studies in MYBPC3-mutant samples, UPS perturbations have also been found in mouse heart tissue with TNNT2 mutations [30]. Patient samples with a sarcomeric mutation showed higher levels of polyubiquitination and decreased proteolytic activity compared to healthy controls [77].

In addition to overload of the UPS by mutant protein, increased oxidative stress can also impair the function of the proteasome. In this case, the proteasomal dysfunction would not be a direct effect of the mutant protein but a consequence of secondary cellular changes. In CM samples, an increase in oxidation of cytosolic protein content as well as the 19S proteasome, thereby decreasing the overall proteolytic function of the 26S proteasome subunit, has been identified [21, 30, 77].

In addition to the proteasome itself, the expression of ubiquitin ligases can be altered. In an HCM mouse model with mutant Mybpc3, the muscle specific E3 ligase Asb2β showed decreased mRNA levels compared to wild-type mice [99]. Since one of its targets is desmin, accumulation of desmin could contribute to the HCM phenotype, as observed for desmin-related CMs.

A large HCM patient cohort and matched healthy controls were screened for genetic variants in all three members of the MuRF family, since mutations in the gene encoding MuRF1 were reported to cause HCM [18]. In this study, a higher prevalence of rare variants of the cardiac-specific E3 ligases MuRF1 and MuRF2 was found in HCM patients [95]. These were associated with earlier disease onset and higher penetrance implying that disturbances of the UPS might act as a disease modifier contributing to HCM.

In contrast to HCM, in DCM, the reported UPS derailments could not yet be linked to sarcomeric mutations. A likely reason for this is that the DCM patient samples did not carry a sarcomeric mutation and/or the underlying disease cause was not known. Tissue analysis from explanted DCM hearts revealed increased expression of both E1 and/or E2 enzymes [47, 108]. Further evidence of increased ubiquitin-conjugating enzyme activity was detected in end-stage DCM. Here, increased levels of MuRF1 and MAFbx were associated with increased UPS degradation activity, which might be the cause of ventricle wall thinning as observed in end-stage DCM patients [9]. In line with the increased ubiquitin-conjugating enzyme levels, increased levels of polyubiquitinated proteins have been detected in DCM samples [11, 47, 72, 108]. This finding is further supported by a 2.3-fold reduced expression of the deubiquitinating enzyme isopeptidase-T in DCM patients [47]. Furthermore, increased proteolytic activity of the 26S proteasome as well as the 20S subunit peptidase activity has been found [9, 11, 72].

In contrast to HSPs, the answer to the question whether UPS activation or inhibition would be beneficial in HCM and DCM is not as straightforward. In an HCM phenotype, proteasomal activation might improve the hypertrophic phenotype due to increased mutant protein degradation. However, in DCM, increased proteasomal function might augment wall thinning, and therefore, DCM might benefit from proteasome inhibition.

**Unresolved role of the autophagic response in cardiomyopathies**

Autophagy is a crucial mechanism in CMs that only fulfills its cytoprotective mechanisms when it is in balance [50]. Moderate activation of autophagy has beneficial effects in CM patients by removing aggregates and supplying the cell with energy.

However, protein degradation due to excessive autophagy has been associated with different types of CM, including HCM, DCM, ischemic CM, and chemotherapy-induced CM [22, 44, 55, 58, 71, 89]. This could lead to loss of myofibrils, as observed in end-stage HCM and DCM patients [40, 70]. In a recent study, the expression of vacuolar protein sorting 34 (Vps34), an important autophagy regulator, was shown to be decreased in the myocardium of HCM patients and deletion of Vps34 resulted in a HCM-like phenotype in mice. Furthermore, decreased expression of Vps34 impaired the HSP-autophagy axis, as indicated by αB-crystallin-positive aggregates [44]. HCM patients with mutations in MYBPC3 or MYH7 revealed an upregulation of autophagic vacuoles and markers, indicated increased autophagic activity [92]. In a homozygous Mybpc3-mutant HCM mouse model, levels of autophagy markers were increased at the protein level implying autophagic activation. However, mRNA levels of these
markers were not increased. This rather suggests an accumulation of autophagic proteins due to defective autophagic-lysosomal degradation instead of activation on transcriptional level [85]. In explanted hearts from DCM patients, the imbalance of high ubiquitination rate and insufficient degradation may contribute to autophagic cell death [47]. Vacuolization in CMs has been reported with mutations in ACTN2, MYBPC3, and NEBL [31, 75, 109]. This observation suggests that the accumulation of autophagic vacuoles implies cardiomyocyte stress. However, the interpretation of vacuole accumulation remains unclear, since it could reflect an increase in autophagic activity or an impairment of autophagosome-lysosome fusion.

For a correct interpretation of the role of autophagy in CM, autophagic flux in combination with gene and protein expression data have to be studied in the future.

Environmental stressors influencing the proteostasis network

Besides the above-mentioned effects of the sarcomeric gene mutations on the PQC, other environmental stressors, including physiological stress, genetic and epigenetic pathways, and inflammation, can also impair its function [82, 120]. In CM patients with a sarcomeric mutation, these stressors can act as second hit and thereby determine disease severity. Since most of CM patients become symptomatic only in a later stage of their life, the influence of drugs directed at the PQC system as treatment modality for co-morbidities and the age-related decline of the PQC are discussed below.

Several anti-cancer agents block the PQC to cause a lethal proteotoxicity in cancer cells. Anthracyclines, for example, directly impair its function by enhancing proteasomal degradation due to increased expression of E3 ligases and increased proteasome activity as well as inhibition of autophagy in cardiomyocytes [2, 27, 51, 63]. Furthermore, they disturb Ca\(^{2+}\) homeostasis, leading to endoplasmic reticulum stress, which derails protein folding [27]. In CM patients, dealing already with a sarcomeric mutation, treatment of another non-cardiac disease can trigger the onset of CM or worsen the clinical outcome. Cardiotoxic side effects of anthracyclines can lead to anthracycline-associated cardiomyopathy (AACM), which presents as LV dysfunction and DCM in adults and RCM in children [53, 61]. Treatment with a low dose of anti-cancer agents induced CM in cancer patients without a history of cardiac disease. Genetic screening of these patients revealed truncating titin variants, which are known as a genetic cause of DCM. These variants may increase the susceptibility for anti-cancer agents-induced CM [52]. In general, patients having a genetic predisposition for DCM are more prone to develop AACM after anthracycline treatment [100, 107]. It can be speculated that the impairment of the PQC due to the anti-cancer treatment is an additional burden to the cardiomyocyte. The clinical cardiac phenotype is caused by insufficient clearance of the mutant protein via UPS and/or autophagy. Therefore, these findings suggest that PQC impairment by anthracyclines can act as catalysts in the development of CM in patients with underlying sarcomeric gene mutation.

Aging represents another cellular stressor leading to toxic mutation effects because of the late disease onset and development of symptoms in inherited CMs. Clinical characteristics, such as wall thickness and diastolic function, worsen with increasing age [57]. This could be related to an age-associated decline in proteostatic function, which is supported by the presence of damaged macromolecules and mitochondria in aged cardiomyocytes [98]. Dysfunctional mitochondria generate high levels of reactive oxygen species, which promote proteotoxic stress and accelerate detrimental effects on the cardiomyocyte [90]. Also, the activity of the 26S proteasome is decreased during aging, which is possibly caused by oxidation of its components [21, 29, 30, 42]. The age-dependent decline in proteasome function increases the burden for the autophagic pathway. However, not only the proteasome, but also the autophagy-lysosomal system declines during aging [81]. As an example, mTOR, a negative regulator of autophagy, was upregulated during aging in a mouse study which indicates decreased autophagic activity [4]. As a result, the activity of the autophagic response might not be sufficient. However, similar to findings related to the UPS, autophagy was enhanced during aging in some animal models, suggesting an increased need for autophagy in aged cells [113]. Further research is warranted to investigate whether the age-related decline of the PQC is causative for CM onset and/or progression.

Future therapeutic implications

To improve the clinical outcome of CM patients, modulation of PQC components might serve as a novel therapeutic strategy. Figure 3 summarizes the three different ways and illustrates how a sarcomeric gene mutation can lead to PQC derailment. In case of a direct mutation effect on the PQC as well as in combination with secondary hits, targeting of the PQC would be most beneficial and the most direct way to prevent cardiomyocyte dysfunction. In case where the PQC derailment is a consequence of mutation-induced cellular disturbances, it is important to also target the cellular dysfunction to prevent further worsening of the PQC.

As extensively discussed in this review, PQC alterations in CMs are disease- and mutation-specific leading to either increased or reduced function in one or several of its components. Therefore, personalized treatment strategies are required to restore a balanced proteostasis. Potentially, all three PQC components can be therapeutically targeted with the appropriate compounds.
HSP expression can be induced by the drug geranylgeranylacetone. In animal models of desmin-related CM, the induction of HSP expression by geranylgeranylacetone resulted in a beneficial effect on heart function because desmin-aggregate formation was reduced [83]. This example suggests that activation of HSPs might also be beneficial in other types of inherited CMs, since HSPs play a crucial role in coping with the mutant protein.

The derailment of the UPS is context dependent: proteasomal function is decreased in HCM, RCM, and desmin-related CM and increased in DCM [9]. Decreased proteasomal function suggests that the misfolded proteins hamper the UPS by overwhelming it due to permanent degradation of misfolded proteins. As a consequence, the activity of the UPS is reduced. Therefore, UPS activation might be a beneficial therapeutic strategy in HCM and desmin-related CM [9]. In line with this, in HCM patients with a TNNT2 mutation increased proteasomal activity was correlated with a better clinical outcome [30]. In contrast, over-activation of the UPS indicates a direct response of the UPS to the misfolded proteins to ensure optimal clearance. However, excessive activation of the UPS transforms the initially beneficial effects into a detrimental maladaptation that possibly contributes to loss of myofibrils [9]. Nevertheless, complete proteasome inhibition itself triggered cardiac dysfunction and a CM-like phenotype in healthy pigs [38]. Therefore, it is important to achieve a moderate UPS response in DCM to prevent the detrimental effects of complete proteasome inhibition.

The altered autophagic flux in CMs can be caused on the one hand directly by the misfolded protein itself or on the other hand indirectly by compensating for the impaired functionality of the UPS. To optimize the degradation response, the autophagic activity needs to be pharmacologically titrated into its proteostasis promoting range [114].

Conclusion

The PQC is crucial for cardiac health and requires the collaboration of all its components to be functional. Key modulators of the PQC are disease- and mutation-specifically altered and derailed in CM. Pharmacological targeting of PQC components represents a novel therapeutic strategy to treat CMs. Since most of the described findings are retrieved from single CM patients or experimental animal models, systematic studies in larger CM patient populations are warranted to untie the knot of disease- and mutation-specific derailments of the PQC.

Acknowledgements

We acknowledge support from the Netherlands Cardiovascular Research Initiative—an initiative with support of the Dutch Heart Foundation, CVON: The Netherlands CardioVascular Research Committee, CVON2014-40 DOSIS. Furthermore, this research has been supported by LSH-TKI (40-43100-98-008), the Dutch Heart Foundation (2013T096, 2013T144), and the Netherlands Organisation for Scientific Research (NWO), as part of their joint strategic research programme: “Earlier recognition of cardiovascular diseases” (AFFIP: 14728). Van der Velden is...
supported by a VICI grant from the Netherlands Organization for Scientific Research (NWO-ZonMW; 91818602).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Amm I, Sommer T, Wolf DH (2014) Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochim Biophys Acta 1843:182–196. https://doi.org/10.1016/j.bbamcr.2013.06.031
2. Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kuranabayashi M, Nagai R (2000) Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 86:8–14
3. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Fava V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol 62:2046–2072. https://doi.org/10.1016/j.jacc.2013.08.1644
4. Baar EL, Carbajal KA, Ong JM, Lamming DW (2016) Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging Cell 15:155–166. https://doi.org/10.1111/acel.12425
5. Baba M, Takeshige K, Baba N et al (1994) Ultrastructural analysis of the autophagic process in yeast: detection of autophagosomes and their characterization. J Cell Biol 124:903–913
6. Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Namba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto K, Shirayoshi Y, Kitakaze M, Carrier L, Hisatome I (2008) Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 86:896–907. https://doi.org/10.1161/jr.0000000000000070
8. Barral JM, Epstein HF (1999) Protein machines and self assembly in muscle organization. Bioessays 21:813–823. https://doi.org/10.1002/(SICI)1521-1878(199910)21:10<813::AID-BIES3>3.0.CO;2-0
9. Baumgarten A, Bang C, Tschirner A, Engelmann A, Adams V, von Haehling S, Doehner W, Pregla R, Anker MS, Bleharz K, Meyer R, Hetzer R, Anker SD, Thum T, Springer J (2013) TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. Int J Cardiol 168:1447–1452. https://doi.org/10.1016/j.ijcard.2012.12.094
10. Bennardini F, Wrzosek A, Chiesi M (1992) Alpha B-crystallin in cardiac tissue. Association with actin and desmin filaments. Circ Res 71:288–294
11. Birks EJ, Latif N, Enea K, Folkvang T, Luong LA, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJR, Yacoub MH, Evans PC (2008) Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79:472–480. https://doi.org/10.1093/cvr/cvn083
12. Boateng SY, Goldspink PH (2008) Assembly and maintenance of the sarcomere night and day. Cardiovasc Res 77:667–675. https://doi.org/10.1093/cvr/cvm048
13. Bozyakut P, Ozer NK, Karademir B (2014) Regulation of protein turnover by heat shock proteins. Free Radic Biol Med 77:195–209. https://doi.org/10.1016/j.freeradbiomed.2014.08.012
14. Brown DD, Christine KS, Showell C, Conlon FL (2007) Small heat shock protein Hsp27 is required for proper heart tube formation. Genesis 45:667–678. https://doi.org/10.1002/dvg.20340
15. Brundel BJ, Shiroshita-Takeshita A, Qi X et al (2006) Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 99:1394–1402. https://doi.org/10.1161/01.RES.0000252323.83137.fe
16. Bryantsev AL, Loktionova SA, Ilyinskaya OP, Tararak EM, Meyer R, Hetzer R, Anker SD, Thum T, Springer J (2013) Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circ Heart Fail 6:544–559. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000119
17. Bryantsev AL, Loktionova SA, Ilyinskaya OP, Tararak EM, Kampinga HH, Kabakoe AE (2002) Distribution, phosphorylation, and activities of Hsp25 in heat-stressed H9c2 myoblasts: a functional link to cytoprotection. Cell Stress Chaperones 7:146–155
18. Cecconi F, Levine B (2008) The role of autophagy in mammalian development: cell movement rather than cell death. Dev Cell 15:344–357. https://doi.org/10.1016/j.devcel.2008.08.012
19. Chen SN, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson JT, Marian AJ (2012) Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 111:907–919. https://doi.org/10.1161/CIRCRESAHA.112.270207
20. Chen XM, Feng MJ, Shen CJ, He B, du XF, Yu YB, Liu J, Chu HM (2017) A novel approach to select differential pathways associated with hypertrophic cardiomyopathy based on gene coexpression analysis. Mol Med Rep 16:1767–1773. https://doi.org/10.3892/mmr.2017.6667
21. Cui Z, Venkatraman G, Hwang SM et al (2013b) Effect of the cardiomyopathy mutation R145W on protein expression in murine hearts. Biophys J 104:312a
22. Day SM, Divald A, Wang P, Davis F, Bartolone S, Jones R, Powell SR (2013) Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circ Heart Fail 6:544–549. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000119
23. Decker RS, Wildenthal K (1980) Lysosomal alterations in hypoxic tissues. Circ Res 47:207–211. https://doi.org/10.1161/01.RES.0000527072.1402
24. Ehmsperger M, Lilie H, Gaestel M et al (1999) The dynamics of Hsp25 quaternary structure. Structure and function of different oligomeric species. J Biol Chem 274:14867–14874
25. Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276. https://doi.org/10.1093/eurheartj/ehm342
26. Esser C, Alberti S, Hohlfeld J (2004) Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim
Biophys Acta 1695:171–188. https://doi.org/10.1016/j.bbamer.2004.09.020

26. Finley D (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78:477–513. https://doi.org/10.1146/annurev.biochem.78.051507.101607

27. Fu HY, Sanada S, Matsuzaki T, Liao Y, Okuda K, Yamato M, Tsuchida S, Araki R, Asano Y, Asanuma H, Asakura M, French BA, Sakata Y, Kitakaze M, Minamino T (2016) Chemical endo-plasmic reticulum chaperone alleviates doxorubicin-induced cardiac dysfunction. Circ Res 118:798–809. https://doi.org/10.1161/CIRCRESAHA.115.307604

28. Garrido C, Paul C, Seigneuric R, Kampinga HH (2012) The small heat shock proteins family: the long forgotten chaperones. Int J Biochem Cell Biol 44:1588–1592. https://doi.org/10.1016/j.biocel.2012.02.022

29. Gilda JE, Gomes AV (2017) Proteasome dysfunction in cardiomyopathies. J Physiol 595:4051–4071. https://doi.org/10.1113/JP273607

30. Gilda JE, Lai X, Witzmann FA, Gomes A V (2016) Delineation of molecular pathways involved in cardiomyopathies caused by troponin T mutations. Mol Cell Proteomics 15:1962–1981. https://doi.org/10.1074/mcp.M115.057380

31. Girolami F, Iascone M, Tomberli B, Sarti C, Benelli M, Marseglia G, Pescucci C, Pezzoli L, Sana ME, Basso C, Marziliano N, Merlini PA, Formaro A, Cecchi F, Torricelli F, Olivotto I (2014) Novel alpha-actinin-2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Cire Cardiovasc Genet 7:741–750. https://doi.org/10.1161/CIRCGENETICS.113.004886

32. Glazier AA, Hafeez N, Mellacheruvu D, Basrur V, Nesvizhskii AI, Glazier AA, Hafeez N, Mellacheruvu D, Basrur V, Nesvizhskii AI, Lee LM, Shao H, Tang Y, Yob JM, Gestwicki JE, Helms AS, Day PL (2013) HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C. JCI Insight 3. https://doi.org/10.1172/jci.insight.99319

33. Golenhofen N, Perring MD, Quinlan RA et al (2004) The small heat shock proteins alphaB-crystallin, MKBP, HSP25, and cvHSP in heart and skeletal muscle. Histochem Cell Biol 122:415–425. https://doi.org/10.1007/s00418-004-0711-7

34. Grantham J, Ruddock LW, Roobol A, Carden MJ (2002) Novel alpha-actinin-2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Cire Cardiovasc Genet 7:741–750. https://doi.org/10.1161/CIRCGENETICS.113.004886

35. Gustafsson AB, Gottlieb RA (2008) Recycle or die: the role of autophagy in cardioprotection. J Mol Cell Cardiol 40:451–457. https://doi.org/10.1016/j.yjmcc.2007.12.018

36. Hanson WJ, Cowan NJ, Welch WJ (1999) Prefoldin-nascent chain conjugates by the proteasome system with the cardiomyopathy phenotype in cardiac myosin binding protein C. JCI Insight 3. https://doi.org/10.1172/jci.insight.99319

37. Henning RH, Brandel B (2017) Proteostasis in cardiac health and disease. Nat Rev Cardiol 14:637–653. https://doi.org/10.1038/nrcardio.2017.89

38. Herrmann J, Wohlfert C, Saguner AM, Flores A, Nesbitt LL, Ivandic BT, Mastitsky SE, Schonsiegel F et al (2012) Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains. Cardiovasc Res 94: 87–95. https://doi.org/10.1093/cvr/cvs080

39. Herrmann J, Wohlfert C, Saguner AM, Flores A, Nesbitt LL, Ivandic BT, Mastitsky SE, Schonsiegel F et al (2012) Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains. Cardiovasc Res 94: 87–95. https://doi.org/10.1093/cvr/cvs080

40. Herrmann J, Wohlfert C, Saguner AM, Flores A, Nesbitt LL, Ivandic BT, Mastitsky SE, Schonsiegel F et al (2012) Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains. Cardiovasc Res 94: 87–95. https://doi.org/10.1093/cvr/cvs080

41. Herrmann J, Wohlfert C, Saguner AM, Flores A, Nesbitt LL, Ivandic BT, Mastitsky SE, Schonsiegel F et al (2012) Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains. Cardiovasc Res 94: 87–95. https://doi.org/10.1093/cvr/cvs080

42. Herrmann J, Wohlfert C, Saguner AM, Flores A, Nesbitt LL, Ivandic BT, Mastitsky SE, Schonsiegel F et al (2012) Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains. Cardiovasc Res 94: 87–95. https://doi.org/10.1093/cvr/cvs080
100:914–922. https://doi.org/10.1161/01.RES.0000261924.76669.36

59. Mcelhinny AS, Perry CN, Witt CC et al (2004) Muscle-specific RING finger-2 (MURF-2) is important for microtubule, intermediate filament and sarcomeric M-line maintenance in striated muscle development. J Cell Sci 117:3175–3188. https://doi.org/10.1242/jcs.01158

60. Meijering RA, Zhang D, Hooistra-Berends F et al (2012) Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins. Front Physiol 3:36. https://doi.org/10.3389/fphys.2012.00036

61. Meinardi MT, Van Der Graaf WT, Van Veldhuisen DJ et al (1999) Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25:237–247. https://doi.org/10.1053/ctr.1999.0128

62. Min TJ, Jo WM, Shin SY, Lim HE (2015) The protective effect of heat shock protein 70 (Hsp70) in atrial fibrillation in various cardiomyopathy conditions. Heart Vessel 30:379–385. https://doi.org/10.1007/s00380-014-0521-8

63. Minotti G, Licata S, Saponiero A, Menna P, Calafio AM, di Giannmarco G, Liberi G, Animati F, Cippolone A, Mannini S, Maggi CA (2000) Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel discarachide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 13:1336–1341

64. Miyamoto CA, Fischman DA, Reinach FC (1999) The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C. J Muscle Res Cell Motil 20:703–715

65. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2008) Proteotoxic stress and inducible chaperone protein turnover by acetyltransferases and deacetylases. Biochimie 90:306–312. https://doi.org/10.1016/j.biochi.2007.06.009

66. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2008) Autophagosome marker. Mol Biol Cell 15:1101–1111. https://doi.org/10.1091/mbc.E07-09-0704

67. Mundia MM, Demers RW, Chow ML, Perieteanu AA, Dawson JF (2012) Subdomain location of mutations in cardiac actin correlate with severity and prognosis in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 102:606–610. https://doi.org/10.1016/j.amjcard.2008.04.030

68. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, Wolska B, Evans C, Solaro RJ, Wieczorek DF (1999) Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-actinin 2. Circulation 99:817–821. https://doi.org/10.1161/01.CIR.99.10.817

69. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, Wolska B, Evans C, Solaro RJ, Wieczorek DF (1999) Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-actinin 2. Circulation 99:817–821. https://doi.org/10.1161/01.CIR.99.10.817

70. Nijenkamp L, Bollen IE, Van Velzen HG et al (2018) Sex differences at the time of myectomy in hypertrophic cardiomyopathy. J Cell Sci 131:jcs214083. https://doi.org/10.1242/jcs.214083

71. Nowis D, Maczewski M, Mackiewicz U et al (2010) Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 176:1427–1438. https://doi.org/10.1016/j.ajpath.2009.11.023

72. Otsuka K, Terasaki F, Shimomura H, Tsakada B, Horii T, Isomura T, Suma H, Shibayama Y, Kitaura Y (2010) Enhanced expression of the heat shock protein 70 (Hsp70) in atrial fibrillation in various cardiomyopathy conditions. Heart Vessel 30:379–385. https://doi.org/10.1007/s00380-014-0521-8

73. Patterson C, Ike C, Willis PWT et al (2007) The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation 115:1456–1463. https://doi.org/10.1161/CIRCULATIONAHA.106.649863

74. Peddy SB, Vicella LA, Crosson JE et al (2006) Infantile restrictive cardiomyopathy resulting from a mutation in the cardiac troponin T gene. Pediatrics 117:1830–1833. https://doi.org/10.1542/peds.2005-2301

75. Perrot A, Tomasov P, Villard E et al (2016) Mutations in NEBL encoding the cardiac Z-disk protein nebulette are associated with various cardiomyopathies. Arch Med Sci 12:263–278. https://doi.org/10.5114/ams.2016.59250

76. Ploski R, Rydzanicz M, Ksiazczyk TM, Franaszczuk M, Pollak A, Kosinska J, Michalak E, Stawiński P, Ziolkowska L, Bilinska ZT, Werner B (2016) Evidence for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. Am J Med Genet A 170:3241–3248. https://doi.org/10.1002/ajmg.a.37860

77. Predmore JM, Wang G, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR, Day SM (2010) Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121:997–1004. https://doi.org/10.1161/CIRCULATIONAHA.109.904557

78. Purevjav E, Varela J, Morgado M, Kearney DL, Li H, Taylor MD, Arimura T, Moncman CL, McKenna W, Murphy RT, Lebit S, Vatta M, Bowles NE, Kimura A, Boriek AM, Toubin JA (2010) Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol 56:1493–1502. https://doi.org/10.1016/j.jacc.2010.05.045

79. Rajan S, Ahmed RP, Jagathesan G et al (2007) Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofila-mentum calcium sensitivity. Circ Res 101:205–214. https://doi.org/10.1161/CIRCRESAH.107.148379

80. Ravid T, Hochstrasser M (2008) Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9:679–690. https://doi.org/10.1038/nrm2468

81. Rubinsztein DC, Marino G, Kroemer G (2011) Autophagy and aging. Cell 146:682–695. https://doi.org/10.1016/j.cell.2011.07.030

82. Sadoul K, Boyault C, Pabion M, Khochbin S (2008) Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90:306–312. https://doi.org/10.1016/j.biochi.2007.06.009

83. Sanbe A, Daicho T, Mizzutan T, Endo T, Yamauchi J, Takanaka K, Glabe C, Tanoue A (2009) Protective effect of geranylgeranylationce via enhancement of HSPB3 induction in desmin-related cardiomyopathy. PLoS One 4:e3531. https://doi.org/10.1371/journal.pone.0003531

84. Sarikas A, Carrier L, Schenck C et al (2005) Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 66:33–44. https://doi.org/10.1016/j.cardiores.2005.01.004

85. Schlossarek S, Englmann DR, Sultan KR, Sauer M, Eschenhagen T, Carrier L (2012) Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. Basic Res Cardiol 107:235. https://doi.org/10.1007/s00395-011-0235-3

86. Scott RC, Schuldiner O, Neufeld TP (2004) Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev Cell 7:167–176. https://doi.org/10.1016/j.devcel.2004.07.009

87. Sekiguchi D, Mizutani R, Burton BK et al (2009) Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol 65:83–89. https://doi.org/10.1002/ana.21553

88. Semersarian C, Ingles J, Wilde AA (2015) Sudden cardiac death in the young: the molecular autopsy and a practical approach to sur-viving relatives. Eur Heart J 36:1290–1296. https://doi.org/10.1093/eurheartj/ehv063

89. Shimomura H, Terasaki F, Hayashi T, Kitaura Y, Isomura T, Suma H (2001) Autophagic degeneration as a possible...
mechanism of myocardial cell death in dilated cardiomyopathy. Jpn Circ J 65:965–968
90. Simonsen A, Cumming BR, Brech A, Isaksen P, Schubert DR, Finley KD (2008) Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult Drosophila. Autophagy 4:176–184
91. Solomon V, Goldberg AL (1996) Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271: 26690–26697
92. Song L, Su M, Wang S, Zou Y, Wang X, Yang, Cui H, Zhao P, Zhou X, Hui R, Song L (2014) Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. J Mol Cell Med 18:2266–2274. https://doi.org/10.1111/jcmj.12380
93. Spencer JA, Eliazer S, Ilaria RL Jr, Richardson JA, Olson EN (2000) Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J Cell Biol 150:771–784
94. Srikakulam R, Winkelmann DA (2004) Chaperone-mediated folding and assembly of myosin in striated muscle. J Cell Sci 117:641–652. https://doi.org/10.1242/jcs.008899
95. Su M, Wang J, Kang L, Wang Y, Zou Y, Feng X, Wang D, Ahmad F, Zhou X, Hui R, Song L (2014) Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. J Mol Cell Sci 15:9302–9313. https://doi.org/10.1390/jms.15069302
96. Tannous P, Zhu H, Nemchenko A, Berry JM, Johnstone JL, Sum W, Wang J, Kang L, Wang Y, Zou Y, Feng X, Wang D, Ahmad F, Zhou X, Hui R, Song L (2014) Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. J Mol Cell Med 18:2266–2274. https://doi.org/10.1111/jcmj.12380
97. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Shelton JM, Miller FJ, Rothermel BA, Hill JA (2008) Intracellular protein aggregation is a proximal trigger of cardiomyocyte dysfunction. Circulation 119:1473–1483. https://doi.org/10.1161/CIRCULATIONAHA.107.763899
98. Terman A, Dalen H, Eaton JW, Neuzil J, Brunk UT (2003) Mitochondrial recycling and aging of cardiac myocytes: the role of autophagocytosis. Exp Gerontol 38:863–876
99. Thottakara T, Friedrich FW, Reischmann S, Braumann S, Schlossarek S, Krämer E, Juhr D, Schlüter H, van der Velden J, Möllmann M, Schiergens T, Morgenstern B, Schlüter H, von der Velden J, München J, Patten M, Eschenhagen T, Moog-Lutz C, Carlier L (2015) The E3 ubiquitin ligase Asb2beta regulates the activity of the autophagy receptor p62 in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation. J Mol Cell Cardiol 87:214–224. https://doi.org/10.1016/j.mcc.2015.08.020
100. Van Den Berg MP, Van Spaendonk-Zwarts KY, Van Veldhuisen DJ et al (2010) Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? Eur J Heart Fail 12: 1297–1299. https://doi.org/10.1093/eurjhf/hfq175
101. Van Dijk SJ, Dooijes D, Dos Remedios C et al (2009) Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119:1473–1483. https://doi.org/10.1161/CIRCULATIONAHA.108.838672
102. Vang S, Corydon TJ, Borglund AD et al (2005) Actin mutations in hypertrophic and dilated cardiomyopathy cause inefficient protein folding and perturbed filament formation. FEBS J 272:2037–2049. https://doi.org/10.1111/j.1742-4658.2005.04630.x
103. Vos MJ, Kanon B, Kampina GH (2009) HSPB7 is a SC35 speckle resident small heat shock protein. Biochim Biophys Acta 1793: 1343–1353. https://doi.org/10.1016/j.bbamcr.2009.05.005
104. Wang J, Maldonado MA (2006) The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3:255–261
105. Wang X, Olsinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J, Hewett T, Robbins J (2001) Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 89:84–91
106. Wang X, Su H, Ranek MJ (2008) Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol 45:11–27. https://doi.org/10.1016/j.yjmcc.2008.03.025
107. Wasielewski M, Van Spaendonk-Zwarts KY, Westerink ND et al (2014) Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart 1:e000116. https://doi.org/10.1136/openheart-2014-000116
108. Weekees J, Morrison K, Mullens A, Waiz R, Barton P, Dunn MJ (2003) Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3:208–216. https://doi.org/10.1002/pmic.200390029
109. Wessels MW, Herkert JC, Frohn-Mulder IM, Dallinghaus M, van den Winggaard A, de Kruijer RK, Michels M, de Coo IJM, Hoedemaekers YM, Dooves J (2015) Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. Eur J Hum Genet 23: 922–928. https://doi.org/10.1038/ejhg.2014.211
110. Wijkeren PJ, Friedrich FW, Dutsch A et al (2016) Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. J Mol Cell Cardiol 97:82–92. https://doi.org/10.1016/j.yjmcc.2016.03.003
111. Willis MS, Patterson C (2010) Hold me tight: role of the heat shock protein family of chaperones in cardiac disease. Circulation 122:1740–1751. https://doi.org/10.1161/CIRCULATIONAHA.110.942250
112. Willis MS, Schisler JC, Portbury AL et al (2009) Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 81:439–448. https://doi.org/10.1093/cvr/cvn009
113. Wohlgemuth SE, Julian D, Akin DE, Fried J, Toscano K, Leeuwenburgh C, Dunn WA Jr (2007) Autophagy in the heart and liver during normal aging and calorie restriction. Rejuvenation Res 10:281–292. https://doi.org/10.1089/rej.2006.0535
114. Xie M, Morales CR, Lavandero S, Hill JA (2011) Tuning flux: autophagy as a target of heart disease therapy. Curr Opin Cardiol 26:216–222. https://doi.org/10.1097/HCO.0b013e328345980a
115. Yan L, Vanner DE, Kim SJ, Ge H, Masurekar M, Massover WH, Yang G, Matsui S, Sadoshima J, Vatter SF (2005) Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci U S A 102: 13807–13812. https://doi.org/10.1073/pnas.0500843102
116. Yang Q, Olsinska H, Klevitsky R, Robbins J (2001) Phenotypic deficits in mice expressing a myosin binding protein C lacking the titin and myosin binding domains. J Mol Cell Cardiol 38: 1319–1324. https://doi.org/10.1006/jmcc.2001.12389
117. Yorimitsu T, Klionsky DJ (2005) Autophagy: molecular machin-...